nach oben

Erschienen in:

01.10.2015 | Short Communication

Selected commentary to “Treatment of Barrett’s esophagus with a novel focal cryoablation device: a safety and feasibility study”

verfasst von: I. Kristo, MD, F. M. Riegler, MD, R. Asari, MD, E. Cosentini, MD, Univ.-Prof. Dr. S. F. Schoppmann, MD

Erschienen in: European Surgery | Ausgabe 5/2015

Einloggen, um Zugang zu erhalten

Excerpt

Barrett’s esophagus (BE) is caused by gastroesophageal reflux disease (GERD) and harbors an increased risk for esophageal cancer [1‐3]. Via a sequence involving low- (LGD) and high-grade dysplasia (HGD), esophageal adenocarcinoma may develop (annual cancer risk: 0.1–0.7 %) [4, 5]. Indefinite for dysplasia (ID) defines a condition where the presence or absence of dysplasia cannot be accurately assessed, due to inflammatory changes in the mucosa. Re-endoscopy and biopsy sampling is recommended after a 3–4 weeks course of double dose proton pump inhibitor (PPI) therapy p.o. (i.e. 2 × 40 mg PPI). Diagnosis of BE is established if biopsies obtained from endoscopically visible segments, tongues or islands of columnar lined esophagus (CLE) contain goblet cells ± LGD, HGD or cancer [6]. …

Vorheriger Artikel Retroperitoneal necrotizing fasciitis secondary to Fournier’s gangrene

Nächster Artikel Erratum to: 8th annual meeting of Chinese College of Surgeons and 19th annual meeting of the European Society of Surgery

Lenglinger J, Riegler M, Cosentini E, Asari R, Mesteri I, Wrba F, Schoppmann SF. Review on the annual cancer risk of Barrett’s esophagus in persons with symptoms of gastroesophageal reflux disease. Anticancer Res. 2012;32(12):5465–73.PubMed

Kristo I, Schoppmann SF. Diagnosis and treatment of benign esophageal diseases. Eur Surg. 2015. (Epub ahead of print)

Chandrasoma PT. Columnar lined esophagus: what it is and what it tells us. Eur Surg. 2006;38(3):197–209.CrossRef

Schwameis K, Ba-Ssalamah A, Wrba F, Birner P, Prager G, Hejna M, Schmid R, Asari R, Zacherl J, Schoppmann SF. The implementation of minimally-invasive esophagectomy does not impact short-term outcome in a high-volume center. Anticancer Res. 2013;33(5):2085–91.PubMed

Riegler FM. Barrett’s esophagus: filling the gap. Eur Surg. 2010;42(1):1–3.CrossRef

Lenglinger J, See SF, Beller L, Cosentini EP, Asari R, Wrba F, Riegler M, Schoppmann SF. Review on novel concepts of columnar lined esophagus. Wien Klin Wochenschr. 2013;125(19–20):577–90.CrossRefPubMed

Small AJ, Araujo JL, Leggett CL, Mendelson AH, Agarwalla A, Abrams JA, Lightdale CJ, Wang TC, Iyer PG, Wang KK, Rustgi AK, Ginsberg GG, Forde KA, Gimotty PA, Lewis JD, Falk GW, Bewtra M. Radiofrequency ablation is associated with decreased neoplastic progression in patients with Barrett’s esophagus and confirmed low-grade dysplasia. Gastroenterology. 2015. (Epub ahead of print)

Haidry RJ, Butt MA, Dunn JM, Gupta A, Lipman G, Smart HL, Bhandari P, Smith L, Willert R, Fullarton G, Pietro M D, Gordon C, Penman I, Barr H, Patel P, Kapoor N, Hoare J, Narayanasamy R, Ang Y, Veitch A, Ragunath K, Novelli M, Lovat LB, Registry UR. Improvement over time in outcomes for patients undergoing endoscopic therapy for Barrett’s oesophagus-related neoplasia: 6-year experience from the first 500 patients treated in the UK patient registry. Gut. 2015;64(8):1192–9.PubMedCentralCrossRefPubMed

Phoa KN, Pouw RE, Bisschops R, Pech O, Ragunath K, Weusten BL, Schumacher B, Rembacken B, Meining A, Messmann H, Schoon EJ, Gossner L, Mannath J, Seldenrijk CA, Visser M, Lerut T, Seewald S, Ten Kate FJ, Ell C, Neuhaus H, Bergman JJ. Multimodality endoscopic eradication for neoplastic Barrett oesophagus: results of an European multicentre study (EURO-II). Gut. 2015. (Epub ahead of print)

10.

Mestari I, Beller L, Fischer-See S, Schoppmann S, Lenglinger J, Wrba F, Riegler M, Zacherl J. Radiofrequency ablation of Barrett’s esophagus and early cancer within the background of the pathophysiology of the disease. Eur Surg. 2012;44(6):366–82.CrossRef

11.

Arora G, Basra S, Roorda AK, Triadafilopoulos G. Radiofrequency ablation of Barrett’s esophagus. Eur Surg. 2009;41(1):19–25.CrossRef

12.

Subramanian CR, Triadafilopoulos G. Radiofrequency-based treatments for esophageal disease. Eur Surg. 2014;46(1):12–20.CrossRef

13.

Haidry RJ, Lipman G, Banks MR, Butt MA, Sehgal V, Graham D, Dunn JM, Gupta A, Sweis R, Miah H, Morris D, Smart HL, Bhandari P, Willert R, Fullarton G, Morris J, Pietro M D, Gordon C, Penman I, Barr H, Patel P, Boger P, Kapoor N, Mahon B, Hoare J, Narayanasamy R, O’Toole D, Cheong E, Direkze NC, Ang Y, Veitch A, Dhar A, Nyalender D, Ragunath K, Leahy A, Fullard M, Rodriguez-Justo M, Novelli M, Lovat LB. Comparing outcome of radiofrequency ablation in Barrett’s with high grade dysplasia and intramucosal carcinoma: a prospective multicenter UK registry. Endoscopy. 2015. (Epub ahead of print)

14.

Kristo I, Asari R, Rieder E, Riegler V, Schoppmann SF. Treatment of Barrett’s esophagus: update on new endoscopic surgical modalities. Minerva Chir. 2015;70(2):107–18.PubMed

15.

Scholvinck DW, Kunzli HT, Kestens C, Siersema PD, Vleggaar FP, Canto MI, Cosby H, Abrams JA, Lightdale CJ, Tejeda-Ramirez E, DeMeester SR, Greene CL, Jobe BA, Peters J, Bergman JJ, Weusten BL. Treatment of Barrett’s esophagus with a novel focal cryoablation device: a safety and feasibility study. Endoscopy. 2015. (Epub ahead of print)

16.

Verbeek RE, Vleggaar FP, Ten Kate FJ, van Baal JW, Siersema PD. Cryospray ablation using pressurized CO2 for ablation of Barrett’s esophagus with early neoplasia: early termination of a prospective series. Endosc Int open. 2015;3(2):E107–E12.PubMedCentralCrossRefPubMed

17.

Gosain S, Mercer K, Twaddell WS, Uradomo L, Greenwald BD. Liquid nitrogen spray cryotherapy in Barrett’s esophagus with high-grade dysplasia: long-term results. Gastrointest Endosc. 2013;78(2):260–5.CrossRefPubMed

18.

Shaheen NJ, Greenwald BD, Peery AF, Dumot JA, Nishioka NS, Wolfsen HC, Burdick JS, Abrams JA, Wang KK, Mallat D, Johnston MH, Zfass AM, Smith JO, Barthel JS, Lightdale CJ. Safety and efficacy of endoscopic spray cryotherapy for Barrett’s esophagus with high-grade dysplasia. Gastrointest Endosc. 2010;71(4):680–5.PubMedCentralCrossRefPubMed

19.

Greenwald BD, Dumot JA. Cryotherapy for Barrett’s esophagus and esophageal cancer. Curr Opin Gastroenterol. 2011;27(4):363–7.CrossRefPubMed

20.

Friedland S, Triadafilopoulos G. A novel device for ablation of abnormal esophageal mucosa (with video). Gastrointest Endosc. 2011;74(1):182–8.CrossRefPubMed

21.

Lenglinger J, See SF, Beller L, Cosentini E, Asari R, Wrba F, Riegler M, Schoppmann SF. The cardia: esophageal or gastric? Critical reviewing the anatomy and histopathology of the esophagogastric junction. Acta Chir Iugosl. 2012;59(3):15–26.CrossRefPubMed

Titel: Selected commentary to “Treatment of Barrett’s esophagus with a novel focal cryoablation device: a safety and feasibility study”
verfasst von: I. Kristo, MD
F. M. Riegler, MD
R. Asari, MD
E. Cosentini, MD
Univ.-Prof. Dr. S. F. Schoppmann, MD
Publikationsdatum: 01.10.2015
Verlag: Springer Vienna
Erschienen in: European Surgery / Ausgabe 5/2015
Print ISSN: 1682-8631
Elektronische ISSN: 1682-4016
DOI: https://doi.org/10.1007/s10353-015-0340-x

Springer Medizin Österreich

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2015

Hand-assisted laparoscopic surgery for left sided colorectal cancer: is quality of surgery related with experience?

Pain perception and short-term outcomes in totally laparoscopic colonic surgery with two different fast track programs

Surgery, limos and shine keep things going

Transanal endoscopic microsurgery in treatment of small rectal T1 high-risk, T2 and T3 carcinomas combined with radiochemotherapy

The complex interplay between Notch signaling and Snail1 transcription factor in the regulation of epithelial–mesenchymal transition (EMT)

The assay and clinical significance of serum thymidine kinase 1 in patients with colorectal carcinoma